tfap

TFAP (N-(5-Aminopyridin-2-yl)-4-(trifluoromethyl)benzamide) is a selective cyclooxygenase-1 (COX-1) inhibitor

TFAP4/Wnt/β-catenin-IN-1 (Compound A61) is an orally active inhibitor targeting the TFAP4/Wnt/β-catenin pathway. Known for its potent anticancer properties, it effectively targets various cancer cells, including those of gastric, lung, and breast cancer, with the strongest activity observed in MGC-803 gastric cancer cells (IC50: 3.92 μM). By inhibiting the TFAP4/Wnt/β-catenin signaling pathway, it induces apoptosis and S phase cell cycle arrest. TFAP4/Wnt/β-catenin-IN-1 is applicable for gastric cancer research.

TFAP2β modulator-1 (compound A6) is a potent TFAP2β modulator that enhances the aggregation of TFAP2β by inducing conformational changes in its intrinsically disordered regions. The compound induces apoptosis and exhibits antitumor activity in esophageal squamous cell carcinoma (ESCC) cells, mouse models, and organoids. TFAP2β modulator-1 is applicable for research related to ESCC.

FT-FAPI-12_9 (TFA) serves as an FAP ligand, utilized in synthesizing the FAP-targeted radiotracer FAPI-46.

NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor and structural analogue of FAPI-4. NOTA-FAPI-4 serves as a diagnostic and therapeutic tool for diseases characterized by FAP overexpression, including its application as a positron emission tomography (PET) tracer for noninvasive imaging of FAP-associated pathological conditions and monitoring of therapeutic responses.